(Q34540317)

2 August 2017

1 reference

title

Discovery of TNF-alpha as a therapeutic target in rheumatoid arthritis: preclinical and clinical studies (English)

1 reference

2 August 2017

0 references

1 reference

Marc Feldmann

1

1 reference

PubMed ID

11858351

2 August 2017

Ravinder N Maini

series ordinal

2

1 reference

2 August 2017

1 January 2002

1 reference

2 August 2017

1 reference

2 August 2017

69

1 reference

2 August 2017

1

1 reference

2 August 2017

12-18

1 reference

The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Role of cytokines in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Levels of synovial fluid interleukin-1 receptor antagonist in rheumatoid arthritis and other arthropathies. Potential contribution from synovial fluid neutrophils

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Rheumatoid arthritis: a disease of T-lymphocyte/macrophage immunoregulation

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Evidence in support of a self-perpetuating HLA-DR-dependent delayed-type cell reaction in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

The structure of eight distinct cloned human leukocyte interferon cDNAs

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Structure and expression of a cloned cDNA for human interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Nucleotide sequence of human monocyte interleukin 1 precursor cDNA

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned?

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Immunoregulatory role of interleukin 10 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Elevated interleukin-10 levels in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Transforming growth factor beta 1 (TGF-beta 1) induced neutrophil recruitment to synovial tissues: implications for TGF-beta-driven synovial inflammation and hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Pig interleukin 1. Purification of two immunologically different leukocyte proteins that cause cartilage resorption, lymphocyte activation, and fever

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Cytokine production in culture by cells isolated from the synovial membrane

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Measurement of cytokine and adhesion molecule expression in synovial tissue by digital image analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Systemic anti-tumor necrosis factor α therapy in rheumatoid arthritis down-regulates synovial tumor necrosis factor α synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Localization of tumor necrosis factor alpha in synovial tissues and at the cartilage-pannus junction in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Successful transfer of collagen-induced arthritis to severe combined immunodeficient (SCID) mice

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Involvement of endogenous tumor necrosis factor alpha and transforming growth factor beta during induction of collagen type II arthritis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Construction and initial characterization of a mouse-human chimeric anti-TNF antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Analysis of improvement in individual rheumatoid arthritis patients treated with disease-modifying antirheumatic drugs, based on the findings in patients treated with placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Modulation of angiogenic vascular endothelial growth factor by tumor necrosis factor alpha and interleukin-1 in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

Reduction of chemokine levels and leukocyte traffic to joints by tumor necrosis factor alpha blockade in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS1169-8330%2801%2900259-9

7 January 2021

10.1016/S1169-8330(01)00259-9

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11858351